60990-39-8

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 39503-62-3 1-(3-bromo-2-hydroxy-4-methoxy-phenyl)-ethanone 
• 6751-75-3 2-bromoresorcinol 
• 75-36-5 acetyl chloride 

Downstream Products

• 159474-33-6 (2S)-antafumicin B 
• 159216-40-7 (+/-)-2-bromo-1,3-bis(methoxymethoxy)-4-(1-hydroxyethyl)benzene 
• 159216-41-8 (+/-)-2-bromo-1,3-bis(methoxymethoxy)-4-<1-(tert-butyl-dimethylsilyloxy)ethyl>benzene 
• 850398-70-8 1-(3-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 850398-72-0 1-(5-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 850398-71-9 1-(3,5-bis-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 159216-39-4 3-bromo-2,4-bis(methoxymethoxy)acetophenone 

Relevant academic research and scientific papers

IMIDAZOLE CARBOXAMIDES

The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.

Fibrinogen receptor antagonists and their use

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutama

Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: Identification and synthesis of phenyl-tetrazolyl acetophenones

We have identified and synthesized a series of aryl-tetrazoyl acetophenones as positive allosteric potentiators of the metabotropic glutamate receptor 2. Structure activity relationship studies directed toward improving the potency and level of potentiation led to the discovery of 22 (EC50 = 93 nM, 128% potentiation). We have identified and synthesized a series of aryl-tetrazoyl acetophenones as positive allosteric potentiators of the metabotropic glutamate receptor 2. Structure activity relationship studies directed toward improving the potency and level of potentiation led to the discovery of 22 (EC50 = 93 nM, 128% potentiation).

Total syntheses of (2S)-antafumicins A and B.

To clarify the absolute configurations of antafumicins A and B, which are antifungal substances from Aspergillus niger NH-401, the total synthesis of (2S)-antafumicins was accomplished by starting from (S)-malic acid in 12 steps. Based upon the physicochemical data of the synthetic samples, the absolute configurations of naturally occurring antafumicins A and B were determined as (2R,4S)- and (2R,4R)-4-(3-acetyl-2,6-dihydroxyphenyl)-2-methoxy-4-butanolide, respectively.